Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,917 | -41,904 | -33,421 | -22,851 | -11,144 |
| Depreciation Amortization | 41 | 268 | 230 | 125 | 58 |
| Accounts receivable | N/A | N/A | N/A | N/A | -40 |
| Accounts payable and accrued liabilities | 2,663 | -1,185 | -704 | -819 | 19 |
| Other Working Capital | -779 | 2,099 | 1,733 | -475 | -422 |
| Other Operating Activity | -1,662 | 7,973 | 6,891 | 5,082 | 2,421 |
| Operating Cash Flow | $-10,654 | $-32,749 | $-25,271 | $-18,938 | $-9,108 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -221 | -260 | -190 | -64 |
| Investing Cash Flow | $N/A | $-221 | $-260 | $-190 | $-64 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 19 | 19,744 | 19,724 | 19,750 | N/A |
| Financing Cash Flow | $19 | $19,744 | $19,724 | $19,750 | $N/A |
| Beginning Cash Position | 39,838 | 53,064 | 53,064 | 53,064 | 53,064 |
| End Cash Position | 29,203 | 39,838 | 47,257 | 53,686 | 43,892 |
| Net Cash Flow | $-10,635 | $-13,226 | $-5,807 | $622 | $-9,172 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,654 | -32,749 | -25,271 | -18,938 | -9,108 |
| Capital Expenditure | 0 | -221 | -260 | -190 | -64 |
| Free Cash Flow | -10,654 | -32,970 | -25,531 | -19,128 | -9,172 |